Skip to Content

Johnson & Johnson JNJ Stock Quote

| Rating as of


Last close prices updated as of Feb 06, 2023, 7:00 PM EST | USD | BATS BZX Real-Time Price
  • Last Close 163.36
  • Sector Healthcare
  • Industry Drug Manufacturers - General
  • Investment Style Large Blend
  • Day Range 163.10  –  164.85
  • Year Range 155.72  –  186.69
  • Market Cap 427.1020 Bil
  • Volume / Avg 7.0 Mil /  7.1 Mil
  • Price / Sales 4.58
  • Price / Book 5.73
  • Forward Div Yield 2.77%
  • Trailing Div Yield 3.42%

Morningstar‘s Stock Analysis JNJ

Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


A Federal Court’s Ruling to Deny Johnson & Johnson’s Talc Strategy Doesn’t Impact Our Outlook

Damien Conover Sector Director

Analyst Note

| Damien Conover |

A federal court ruling to deny Johnson & Johnson’s legal strategy of placing talc-related litigation into a bankrupt subsidiary doesn’t impact our fair value estimate. We continue to view J&J’s talc-related litigation expenses and reserves of close to $6 billion (along with an additional projected $2 billion) as likely sufficient to cover most of the talc legal costs. Further, we don’t see the litigation threat as impacting the firm’s wide moat that is largely based on intangible assets and switching costs from the drug and device segments. Also, the brand power of the consumer business is partly shielded from the talc controversy, since the firm uses many different branded names (like Neutrogena) that are not closely associated, which reduces the read through from talc to other product lines.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics JNJ

Company Profile JNJ

Business Description

Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women’s health. Geographically, just over half of total revenue is generated in the United States.

One Johnson and Johnson Plaza
New Brunswick, NJ, 08933
Industry Drug Manufacturers - General
Employees 144,300

Related Articles JNJ

FAQs for Johnson & Johnson Stock

Yes. JNJ has a forward dividend yield of 2.75%. See JNJ’s full dividends and stock split history on the Dividend tab.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

JNJ’s market cap is 427.10 Bil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

JNJ’s stock style is Large Core.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

JNJ’s price/sales is 4.62.
Price/sales represents the amount an investor is willing to pay for a dollar generated from a particular company’s sales or revenues.

JNJ’s price/forward earnings is 15.55.
Forward P/E gives some indication of how cheap or expensive a stock is compared with consensus earnings estimates. The lower the Forward P/E, the cheaper the stock.

JNJ’s price/book is 5.73.
Price/book ratio can tell investors approximately how much they’re paying for a company’s assets, based on historical, rather than current, valuations. Historical valuations generally do not reflect a company’s current market value. Value investors frequently look for companies that have low price/book ratios.

See JNJ’s valuation ratios compared to the Market Index.

JNJ’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare JNJ’s historical performance against its industry peers and the overall market.